Amyotrophic lateral sclerosis among patients with a Medicare Advantage prescription drug plan; prevalence, survival and patient characteristics

Print
Related Pages
Pubs
Affiliates Rituparna Bhattacharya [1], Raymond A Harvey [1], Keli Abraham [1], Jon Rosen [1], Paul Mehta [2]

 

[1] Humana Inc.
[2] Agency for Toxic Substances and Disease Registry, Division of Toxicology and Human Health Services
Journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Summary This study estimates ALS prevalence and survival in participants with Medicare. The 5-year period prevalence was 20.5 per 100,000. The 2011-point prevalence for ALS was 11.8 per 100,000. Analyses using Medicare data resulted in higher ALS prevalence estimates than previously reported.
Link tp paper Find the paper here!